Opthea Limited (OPT.AX)
| Previous close | 0.8950 |
| Open | 0.8850 |
| Bid | 0.8650 x 0 |
| Ask | 0.8700 x 0 |
| Day's range | 0.8570 - 0.8850 |
| 52-week range | 0.3150 - 0.9025 |
| Volume | |
| Avg. volume | 5,235,619 |
| Market cap | 1.065B |
| Beta (5Y monthly) | 1.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings date | 30 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Oct 2004 |
| 1y target est | 5.90 |
GlobeNewswireOpthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on Oc
- GlobeNewswire
Opthea Joins the S&P/ASX 300 Index
MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company joins the S&P/ASX 300 Index, effective Monday, September 23, 2024, prior to market open in Australia. “Opthea’s addition to the S&P/ASX 300 Ind
Insider MonkeyOpthea (OPT): Biopharma Innovator on the Verge of a Wet AMD Treatment Revolution
We recently published a list of 7 Best ASX Stocks To Invest In Right Now. In this article, we are going to take a look at where Opthea (NASDAQ:OPT) stands against other ASX stocks to invest in right now. Overview of the Australian Economy According to a report by the Australian Bureau of Statistics, Australia’s […]
